Skip to main content

The RheumNow Week in Review – 9 September 2016

Sep 09, 2016 2:39 pm

Dr. Jack Cush reviews highlight in news and journal reports from this week on

  1. Inflammatory bowel disease patients Rx with TNF inhibitors have no higher risk of renal cell carcinoma; OR 0.8 (0.3-2.5) men & 1.4 (0.2-5.5) women.
  2. Fracture nonunion (~5%) risk increased by RA, OA, diabetes, NSAIDs, opioids, anticoagulants, and anticonvulsants.
  3. In new onset PMR, women report worse general and PMR-specific health problems than men; HAQ, fatigue, sleep, anxiety, depression, etc.
  4. Frequency of IgA Vasculitis in kids has significantly declined between 2003-2012. G I & renal Sxs associated with longer hospital stays.
  5. Dalbeth cautions about Rx asymptomatic hyperuricemia with urate lowering therapy; such patients may be at higher risk of allopurinol toxicity
  6. Subset of primary Sjogrens patients (27%) have anti-CarP Abs that correlate with RF & greater severity (higher focus score)
  7. EU grants approval for Orencia (abatacept; IV or SC) for MTX naive (early) RA patients with moderate-severe disease
  8. 63% of RA patients have some MTX toxicity; 22% its moderate-severe. Giving Caffeine at time of MTX (coffee, Dark chocolate) showed 55% improvedment!
  9. TNFi induced sardoidosis; 90 cases of sarcoidosis ascribed to TNF inhibitor Rx reviewed, most with Enbrel; 71 resolved with discontinuation.
  10. 30% of Biologics us is monotherapy. Choy et al reviews comparative success, reasons, pitfalls of biologic monotherapy
  11. P. Gingivalis Antibodies Antedate Rheumatoid Arthritis Onset. 
  12. Shingles Plus Autoimmune Disease Hikes Stroke Risk by 36-76%
  13. Karolinska Scandal May Undermine the Nobel Prize. 
  14. Is Biologic Safety Different in the Elderly? 
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.